With the global biosensor market expected to grow to $27 billion in 2022, Archer Exploration Limited is in the development of graphene ink compositions and biosensors.
These biological sensor devices are used in the detection and diagnosis of diseases with a potential solution for multiplexing being patented.
They help reduce patients wait times by bypassing traditional requirements and testing processes.
Patented in February 2018 this solution involves the use of graphene, the thinnest material which provides an ultra-sensitive biochemical interface.
However, the chemistry of the graphene surface has limited versatility, but Archer’s technology addresses the challenges associated with introducing selective hierarchal chemistry.
If completed this could enable the technology to be technically and commercially viable in the detection and diagnosis of disease.
Archer has until February 2020 to change from a provisional patent to a full patent.
They are currently in discussions with a German Biotech to continue the development of biosensor technology and to develop long-term agreements.
This collaboration will focus on optimising ink formulations, processing methods, and testing to enable proper functions.
Please find announcement attached here: https://hotcopper.com.au/data/pricesensitive/announcements/ASX/2A1144639_AXE.html